CapsulesClinical Overview
Dabigatran Etexilate is an oral prodrug of dabigatran, a potent, competitive, reversible direct thrombin (Factor IIa) inhibitor on the WHO Model List of Essential Medicines. It binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated conversion of fibrinogen into fibrin and blocking thrombin-induced platelet aggregation. Specific reversal agent (idarucizumab) is available. Indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prophylaxis of DVT and pulmonary embolism.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Swallow capsules whole with a full glass of water, with or without food. Never open, crush, break, or chew capsules, as opening increases oral bioavailability by 75%, drastically increasing bleeding risk. Keep in the original blister pack or desiccant-containing bottle; sensitive to moisture.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dyspepsia, epigastric pain, nausea, minor bleeding, gastrointestinal discomfort. Rare/Severe: Boxed warnings: Thrombotic events after premature discontinuation; spinal/epidural hematomas; major gastrointestinal or intracranial hemorrhage.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warnings for stroke on premature stopping and spinal hematoma. Capsules must be swallowed whole; opening capsules causes dangerous overdose. Predominantly eliminated by kidneys (80%); contraindicated in severe renal impairment (CrCl < 30 mL/min). Contraindicated with mechanical prosthetic heart valves.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Dabigatran Etexilate Mesilate Capsules 110 mg
Dabigatran Etexilate is an oral prodrug of dabigatran, a potent, competitive, reversible direct thrombin (Factor IIa) inhibitor on the WHO Model List of Essential Medicines. It binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated conversion of fibrinogen into fibrin and blocking thrombin-induced platelet aggregation. Specific reversal agent (idarucizumab) is available. Indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prophylaxis of DVT and pulmonary embolism.
Dabigatran Etexilate Mesilate Capsules 75 mg
Dabigatran Etexilate is an oral prodrug of dabigatran, a potent, competitive, reversible direct thrombin (Factor IIa) inhibitor on the WHO Model List of Essential Medicines. It binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated conversion of fibrinogen into fibrin and blocking thrombin-induced platelet aggregation. Specific reversal agent (idarucizumab) is available. Indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prophylaxis of DVT and pulmonary embolism.